Cover Image
Market Research Report

G-Protein Coupled Receptors (GPCRs)

Published by Global Industry Analysts, Inc. Product code 240203
Published Content info 299 Pages
Delivery time: 1-2 business days
Back to Top
G-Protein Coupled Receptors (GPCRs)
Published: April 1, 2012 Content info: 299 Pages

This report analyzes the Global market for G-Protein Coupled Receptors (GPCRs) in US$ Billion. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 43 companies including 7TM Pharma A/S, Actelion Pharmaceuticals Ltd., Acure Pharma AB, Anchor Therapeutics, Arena Pharmaceuticals, Inc., Addex Pharmaceuticals, Acadia Pharmaceuticals Inc., Cara Therapeutics, Inc., DiscoveRx Corporation, Dimerix Bioscience Pty Ltd., Domain Therapeutics, Euroscreen SA, and Trevena, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents
Product Code: MCP-6269

Table of Contents


  • Study Reliability and Reporting Limitations
    • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study



  • A Quick Primer
  • Why GPCRs Are Important?
    • Illustrative Examples of Currently Available Pharmaceutical Drugs Targeting GPCRs
  • Untapped Pharmacological Potential of GPCRs Ignites Interest
    • Popular Types of GPCRs of Therapeutic Interest Currently Being Studied Include:
  • Current Knowledge of GPCR Crystal Structures Just the Tip of the Iceberg
  • NMR Spectroscopy: An Invaluable Tool to Study GPCR Structures
  • Orphan GPCRs: A Promising Area for Drug Discovery
  • Developments in Screening Technology for GPCRs
    • Cell Membrane Assays for GPCR Quantitative Analysis
  • What's in for the Pharmaceutical Industry?
  • Challenges Aplenty in the GPCR Space
    • Addressing Orphan GPCRs
    • Lack of Structural Information
    • Identification and Classification of Allosteric Sites


  • GPCR: Gateways to Cell
  • Classification of GPCRs
    • Table 1: List of Identified Known and Orphan (Non-Sensory) GPCRs in Human Genome (includes corresponding Graph/Chart)
    • Orphan GPCRs and Deorphanization
    • List of oGPCR-Ligand Pairings Identified By Using Reverse Pharmacology Approach
  • Structural Information
    • Rhodopsin: A Well Studied GPCR
    • Crystal Structure of Human Beta-2 Adrenergic GPCR
    • Structure of Human A2A Adenosine Receptor
  • Significance of GPCR Crystal Structures
  • GPCR Signaling Pathways
  • Physiological Roles Performed by GPCRs
    • Visual Sense
    • Cell-density Sensing
    • Regulation of mood and behavior
    • Smelling Sense
    • Regulating Immune-System Inflammation and Activity
    • Automatic Transmission of Nervous System
  • Receptor - Ligand Interaction
    • Types of Ligands
  • Therapeutic Potential of GPCRs
    • List of Major Disease States and Associated Known GPCRs
    • Allosteric Modulators and Implication of Allostery in Drug Discovery
      • Advantages of Allosteric Modulators
    • Dimerisation and Role of Dimers in Drug Discovery
    • Oligomerisation and Role of Oligomers in Drug Discovery
    • Functional Selectivity
    • Existing Drug Candidates in GPCR Space
    • List of Existing GPCR-Based Drugs Available In Market Along With Their Target Receptor and Indication
    • Pipeline GPCR Drug Candidates
  • Ion Channels
  • Approaches to Drug Discovery in GPCR Space
  • Structure-Based Drug Discovery
  • Ligand-Based Drug Discovery
  • Target-Based Drug Discovery
  • GPCR Screening and Targeting Technologies
  • Cell-Based Screening Assays
  • Virtual Screening
  • Fragment screening


  • Domain Therapeutics Enters into an Agreement with Merck Serono
  • Anchor Therapeutics Makes a Breakthrough in GPCR Collaboration
  • Receptos Collaborates with Lilly GPCR target
  • Sanofi-aventis Enters into Licensing Agreement with Metabolex
  • Neurocrine and Boehringer Ingelheim Join Hands to Develop GPR119 Agonists
  • Affitech Enters into Research Collaboration with NTS Plus
  • Takeda Cambridge Inks an Agreement to Utilize Dimerix' GPCR-HIT Platform
  • PerkinElmer Unveils New Detection Kit for Profiling and Screeing GPCRs
  • Omeros Completes Acquisition of GPCR Assay Technology from Patobios
  • DiscoveRx Corporation Takes Over KINOMEscan™
  • Roche and ATCC Collaborate on Real-Time Endogenous GPCR Function Research
  • Millipore Launches Luminescent GPCR Reporter Frozen Cells
  • Ascent Therapeutics re-christened as Anchor Therapeutics
  • Affitech Sells Cancer Vaccine Project to Focus on GPCR Research
  • Medarex Releases Pre-clinical Data for MDX-1338
  • Compugen Declares Positive Therapeutic Effects of CGEN-25009
  • Addex Releases Clinical Data for ADX10059
  • Arana Receives Patent Approval for PMX53 and Related GPCR Compounds
  • Epix Pharmaceuticals Receives Patent Approval for PRX-03140 and Related Compounds
  • Odyssey Thera Receives Patent Approval for Fluorescence-Based Assays
  • Cisbio Bioassays Introduces Cellul'erk Assay
  • DiscoveRx Introduces Products and Services to Assays and Reagents Portfolio
  • PerkinElmer Introduces Novel Ion Channel and GPCR Cell Lines
  • Millipore Launches New AllostericProfilerTM Service
  • Ligand Pharmaceuticals and Trevena Enter into Agreement
  • ChanTest Takes Over ACS
  • PerkinElmer Enters into Collaboration with Sangmyung University
  • Debiopharm Group Inks Exclusive Agreement with MSM Protein Technologies
  • GVK Biosciences and University of Tokyo Sign Agreement
  • MSM Protein Technologies Enters into Alliance with Merck Serono
  • Xenome Enters into Agreement with Axxam
  • DiscoveRx and GlaxoSmithKline Inks Global Agreement
  • Sygnature Enters into Contract Chemistry Agreement with Heptares Therapeutics
  • Enzo Life Sciences Enters into Partnership with BioTek Instruments
  • Heptares Therapeutics Enters into Agreement with Novartis Option Fund
  • CellAura Enters into Partnership with Cisbio Bioassays
  • Euroscreen and Novartis Ink Research Collaboration Agreement
  • Evotec Enters into Co-marketing Agreement with DiscoveRx
  • Jubilant Biosys Inks Co-marketing Agreement with DiscoveRx
  • Faust Pharmaceuticals Changes Name to Domain Therapeutics
  • GSK, MRCT and DiscoveRx Collaborate for Deorphanization of GPCRs
  • DiscoveRx Inks Agreement with BioFocus
  • Actelion's S1P1 Receptor Agonist to Enter into Phase II Clinical Trial
  • AnaSpec Introduces Two Isoform Specific Antibodies
  • Millipore Introduces MultiScreen®HTS+ Filter Plates
  • Faust & Takeda Enter into Research Agreement
  • Caliper Life Sciences Collaborates with DiscoveRx
  • Compugen Inks Agreement with Merck Serono
  • BioFocus and Amgen Extend Drug Discovery Agreement
  • DiscoveRx Selects Cosmo Bio to Distribute GPCR Profiling Service across Japan
  • Euroscreen Extends Agreement with Cephalon
  • BioFocus DPI Introduces Novel Version of GPCR SARfari
  • PerkinElmer Takes Over Euroscreen Products


  • 7TM Pharma A/S (Denmark)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Acure Pharma AB (Sweden)
  • Anchor Therapeutics (USA)
  • Arena Pharmaceuticals, Inc. (US)
  • Addex Pharmaceuticals (Switzerland)
  • Acadia Pharmaceuticals Inc., (USA)
  • Cara Therapeutics, Inc. (USA)
  • DiscoveRx Corporation (USA)
  • Dimerix Bioscience Pty Ltd (Australia)
  • Domain Therapeutics (France)
  • Euroscreen SA (Belgium)
  • Trevena, Inc. (USA)


    • Table 2: World Recent Past, Current & Future Market Analysis for G-Protein Coupled Receptors (GPCRs) Targeting Drugs Analyzed with Annual Sales Figures in US$ Billion for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 3: World Historic Review for G-Protein Coupled Receptors (GPCRs) Targeting Drugs Analyzed with Annual Sales Figures in US$ Billion for Years 2003 through 2008 (includes corresponding Graph/Chart)


Back to Top